Globally, the life sciences sector is working on improving operations and creating new value by transforming digitally. In a highly regulated sector where companies are often fragmented and siloed, transforming at scale can be difficult. For these reasons, it can be helpful for tech function leaders to compare their decision making against their peers in the sector and other industries.
The KPMG global tech report: Life sciences insights examines the views of senior-level life sciences technology function leaders from around the world that include chief digital officers, CIOs, CTOs, CISOs, chief AI officers and others. This report contains valuable insights into how life sciences organizations are navigating the complexities of digital transformation and covers topics that include technology investment decision making, data, AI and cyber security.
KPMG global tech report: Life sciences insights
Beyond the hype: Balancing speed, security and value

Key findings from the research
Read the full report to explore more insights and KPMG life sciences technology specialist perspectives on the findings, and to obtain actionable recommendations for addressing life sciences organization technology challenges.
The insights in this report were derived from the KPMG global tech report 2024, a survey of 2,450 technology leaders from 26 countries across 8 industries: financial services, technology, retail and consumer packaged goods, industrial manufacturing, life sciences, healthcare, government and public sector, and energy. Survey respondents represented organizations with annual operating budgets or revenues above US$100M-plus.
Life sciences respondent demographics: 123 life sciences technology function leaders were surveyed of which a significant portion (85 percent) held C-suite or department head, EVP, SVP or VP level positions. A strong majority (86 percent) of these respondents represented life sciences organizations with revenues of US$10B to US$50B-plus.